You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anti CD19 CAR-T cells

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +15 more
  • Anti-CD19/CD20/CD22 CAR T-Cells
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 4, 2022

B-Cell Non-Hodgkin Lymphoma, DLBCL, Mantle Cell Lymphoma Trial in Duarte (Anti-CD19-CAR CMV-specific T-lymphocytes, Autologous

Not yet recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Anti-CD19-CAR CMV-specific T-lymphocytes
  • +3 more
  • Duarte, California
    City of Hope Medical Center
Jun 28, 2022

B-cell Non Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia Trial in Milwaukee (Dose Level -1: 0.75x10^6 cells/kg

Recruiting
  • B-cell Non Hodgkin Lymphoma
  • B-cell Chronic Lymphocytic Leukemia
  • Dose Level -1: 0.75x10^6 cells/kg CAR20.19.22 cells
  • +3 more
  • Milwaukee, Wisconsin
    Medical College of Wisconsin and Froedtert Hospital
Jul 1, 2022

CD19+ Relapse/Refractory B-ALL Trial in Beijing (CAR-T-19 Cells)

Recruiting
  • CD19+ Relapse/Refractory B-ALL
  • CAR-T-19 Cells
  • Beijing, Beijing, China
    Chinese PLA General Hospital
Feb 26, 2022

Non Hodgkin's Lymphoma Trial in China (Chidamide, Fludarabine and cyclophosphamide, Anti-CD19 CAR-T cells)

Recruiting
  • Non Hodgkin's Lymphoma
  • Beijing, Beijing, China
  • +12 more
Jun 9, 2022

DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Axicabtagene Ciloleucel
  • +10 more
  • (no location specified)
Jan 13, 2023

B-cell Non Hodgkin Lymphoma Trial in Augsburg, Cologne, Hamburg (MB-CART2019.1 Dose level 1, MB-CART2019.1 Dose level 2)

Active, not recruiting
  • B-cell Non Hodgkin Lymphoma
  • MB-CART2019.1 Dose level 1
  • MB-CART2019.1 Dose level 2
  • Augsburg, Bavaria, Germany
  • +2 more
Jun 13, 2022

Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL) Trial in Milwaukee (8/12-Day

Recruiting
  • Non Hodgkin Lymphoma (NHL)
  • +6 more
  • 8/12-Day Production of Car-T Cells
  • +2 more
  • Milwaukee, Wisconsin
    Medical College of Wisconsin and Froedtert Hospital
Jul 1, 2022

Lymphoma, B-Cell, Lymphoma, Non-hodgkins, Chronic Lymphocytic Leukemia Trial run by the NCI (Anti-cluster of differentiation 19

Terminated
Has Results
  • Lymphoma, B-Cell
  • +3 more
  • Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 26, 2022

B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,

Recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 9, 2022

Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL, Relapsed Pediatric ALL Trial in Calgary, Edmonton (autologous CD19-directed

Recruiting
  • Relapsed Non Hodgkin Lymphoma
  • +2 more
  • autologous CD19-directed chimeric antigen receptor (CAR) T-cells
  • Calgary, Alberta, Canada
  • +5 more
Jul 18, 2022

Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia in Children Trial in Singapore (Phase

Recruiting
  • Lymphoblastic Leukemia
  • +4 more
  • Phase I
  • Phase II
  • Singapore, Singapore
    KK Women's and Children's hospital
Jun 20, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jul 14, 2022

Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia Trial in Wuhan (BTK inhibitor+ Fludarabine +

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +4 more
  • BTK inhibitor+ Fludarabine + Cyclophosphamide + CAR-T-CD19 Cells
  • Fludarabine + Cyclophosphamide + CAR-T-CD19 Cells
  • Wuhan, Hubei, China
    Union Hospital, Huazhong University of Science and Technology
Oct 13, 2021

B Cell Lymphoma, B-cell Acute Lymphoblastic Leukemia Trial in Kunming (Anti-CD19 CAR-T Cells Injection)

Recruiting
  • B Cell Lymphoma
  • B-cell Acute Lymphoblastic Leukemia
  • Anti-CD19 CAR-T Cells Injection
  • Kunming, Yunnan, China
    Kunming Yan'an Hospital
May 12, 2021

Chronic GVHD, Hematologic and Lymphocytic Disorder, Steroid Refractory GVHD Trial in Duarte (procedure, biological, other)

Not yet recruiting
  • Chronic Graft Versus Host Disease
  • +2 more
  • Biopsy
  • +11 more
  • Duarte, California
    City of Hope Medical Center
Aug 7, 2023

B-Cell Leukemia, B Cell Lymphoma Trial in Kunming (anti-CD19 UCAR-T injection)

Recruiting
  • B-Cell Leukemia
  • B Cell Lymphoma
  • anti-CD19 UCAR-T injection
  • Kunming, Yunnan, China
    920th Hospital of Joint Logistics Support Force of People's Libe
Apr 21, 2022

Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Leukemia Trial in Chengdu (Modified anti-CD19 CAR T cells)

Active, not recruiting
  • Refractory B-Cell Non-Hodgkin Lymphoma
  • Refractory Leukemia
  • Modified anti-CD19 CAR T cells
  • Chengdu, Sichuan, China
    Sichuan University
Mar 17, 2021

Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8 Trial in Duarte

Recruiting
  • Castration-Resistant Prostate Carcinoma
  • +4 more
  • Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes
  • +3 more
  • Duarte, California
    City of Hope Medical Center
Mar 17, 2022

Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia Trial in Cleveland (Fully human anti CD19 CAR-T

Recruiting
  • Non Hodgkin Lymphoma
  • +2 more
  • Fully human anti CD19 CAR-T Cell Dose
  • +2 more
  • Cleveland, Ohio
    University Hospitals Cleveland Medical Center, Case Comprehensiv
Oct 4, 2022

DLBCL, Not Otherwise Specified, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial in Seattle

Terminated
Has Results
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • +5 more
  • Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 1, 2022

Primary Mediastinal B-cell Lymphoma, Diffuse, Large B-cell Lymphoma, DLBCL Transformed From Follicular Lymphoma Trial run by the

Completed
Has Results
  • Primary Mediastinal B-cell Lymphoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 29, 2021

Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,

Recruiting
  • Lupus Nephritis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Denver, Colorado
  • +1 more
Jul 7, 2023

Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

Not yet recruiting
  • Multiple Sclerosis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Palo Alto, California
    Stanford Multiple Sclerosis Center
Nov 13, 2023

Recurrent Glioblastoma, Refractory Glioblastoma Trial in Duarte (IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory

Recruiting
  • Recurrent Glioblastoma
  • Refractory Glioblastoma
  • IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Oct 29, 2021